Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors

Published:2017-06 Issue:6 Volume:39 Page:101042831770621
ISSN:1010-4283
Container-title:Tumor Biology
language:en
Short-container-title:Tumour Biol.

Author:

Zheng Zhen¹,Xie Deyao²,Su Huafang¹,Lin Baochai¹,Zhao Lihao¹,Deng Xia¹,Chen Hanbin¹,Fei Shaoran¹,Jin Xiance¹,Xie Congying¹

Affiliation:

1. Department of Radiotherapy and Chemotherapy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

2. Department of Thoracic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Publisher

IOS Press

Subject

General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/1010428317706211

Reference23 articles.

1. Targeting EGFR in lung cancer: Lessons learned and future perspectives

2. Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database

3. Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis

4. Malignant effusions: Diagnostic evaluation and therapeutic strategy

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted delivery of epirubicin to cancerous cell using copper sulphide nanoparticle coated with polyarginine and 5TR1 aptamer;Journal of Drug Targeting;2023-10-21

2. Empirical methods for the validation of time-to-event mathematical models taking into account uncertainty and variability: application to EGFR + lung adenocarcinoma;BMC Bioinformatics;2023-09-04

3. Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: A real-world multicentric cohort analysis from India;Current Problems in Cancer;2020-06

4. Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients;Journal of Thoracic Disease;2019-09

5. Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis;Therapeutic Advances in Medical Oncology;2019-01